The 2020 election commentary

The sodium oxybate REMS program: greed isn't good

“…B ack in November 2020, a point in our history that you may recall as marked by, one could say, "disquiet," I wrote a commentary addressing an issue of pharmacoeconomics pertaining to our field (Price, 2020). I acknowledged at the time some trepidation about departing from our core mission of covering psychopharmacology, but argued that the specific topic (dramatic disparities in the pricing of generic psychiatric drugs) was of such great importance to us as psychiatric providers that the exception was justified.…”

A look at the GLP‐1 agonists

“…There were no eye-openers: Their review found that metformin was the best of the lot, with smaller effects seen for histamine 2 receptor antagonists (e.g., ranitidine), but all the findings were "low-certainty" -few studies, small sample sizes, risk of bias. In my commentary for this newsletter back in 2012 (Price, 2012), I called for more widespread use of metformin for this purpose, despite the uncertainties about its benefits, and it's disappointing that there hasn't been a lot more research to study the practice since then.…”